As previously disclosed, on October 8, 2014, Impax Laboratories (Nasdaq: IPXL) entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Tower Holdings, Inc. (“Tower”), Lineage Therapeutics Inc. …
The Wall Street Journal reported Thursday afternoon that Impax Laboratories Inc. (IPXL) is in merger talks with privately ... of 2.25 at $23.80 with volume at nearly a 6-month high. The stock surged to an 11-month high.
Though recent challenges with its manufacturing facility in Hayward, CA involving an FDA Warning Letter & multiple …
A covered call identified by MarketIntelligececenter.com's patented algorithm on Impax Labs Inc (IPXL) could yield about 8.08% (12.58% annualized, for comparison purposes only) in 235 days. Pair a long position in the stock with the Sep …
A month has gone by since the last earnings report for Impax Laboratories, Inc. IPXL. Shares have added about 35.3% in that time frame, outperforming the market. Will the recent positive trend continue leading up to the stock's next …
The stock is trading slightly below its 200-day moving average by 0.40%. Furthermore, shares of Impax Labs, which …
Impax Laboratories Inc. IPXL reported third-quarter 2017 adjusted earnings of ... Amneal Pharmaceuticals entered into an all-stock deal to merge and form a new publicly traded company, Amneal Pharmaceuticals Inc. The combined company …